Established in 1982, we at Randox are dedicated to improving healthcare worldwide with the use of innovative diagnostic technologies. We are passionate about saving lives through the use and development of contemporary and pioneering products. As an international company, headquartered in Northern Ireland, Randox is a major exporter. With having offices and distribution in over 145 countries, manufacturing, and R&D capabilities in 4 jurisdictions across 3 continents.
We are a world leader in the in-vitro diagnostics industry with over 40 years’ experience. Our products offer clinicians and physicians with the most comprehensive insight into patient diagnosis allowing more effective disease management and treatment. Our innovations are not a result of accepting the standard but rooted in our dedication to science and our goal to improving health worldwide. From our diagnostic reagents to quality controls, forensic toxicology to food diagnostics, workplace drug testing to sexual and general health, Randox cultivates lasting relationships with you to improve patient outcomes quickly, accurately, and efficiently.

Our expertise and product portfolio have assisted laboratories across the world in improving diagnostics for clinical healthcare and saving lives. Through a heavily committed research and development programme we continue to offer revolutionary products and solutions specifically designed to provide more efficient, higher quality, and reliable results in the widest variety of laboratory settings. We are advancing the cutting-edge science and technologies that hold the key to ground-breaking improvements in health and practice across the globe.

Improving patient care is our passion. We continually look to develop future innovations believing it is critical to deliver world class heath care solutions right now. Randox is leading the charge in moving from a one-size-fits-all approach towards decisions, practices, and products tailored to the needs of the individual. Our commitment to transforming the lives of patients is matched by our determination to develop new and exciting breakthroughs in science, technology, and engineering.

For more information, visit www.randox.com or email market@randox.com

Transgene is a biotechnology company focused on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer (https://www.transgene.fr/en).

The company currently has several products in clinical development (Phase I and II trials): TG4050, an individualized therapeutic vaccine from the myvac® platform, TG4001, a therapeutic vaccine against HPV-positive cancers, and two oncolytic viruses, TG6002, which enables a chemotherapy to be produced directly in the tumor, and BT-001, the first candidate from the Invir.IO™ platform, armed with an anti-CTLA-4 antibody.

Its two next-generation platforms are based on Transgene’s expertise in viral vector engineering, and precision medicine :

• the myvac® approach allows the generation of individualized vaccine-based immunotherapy that encodes patient-specific mutations (neoantigens) predicted by artificial intelligence,
• the Invir.IO™ platform aims at designing multifunctional oncolytic viruses, built on highly tumor-selective pox vectors, and optimized recombinant payloads.

Transgene also relies on strategy collaborations with recognized industry partners, such as AstraZeneca and Merck KGaA/Pfizer, NEC, and BioInvent.

The Company is based in Strasbourg, France, and has additional operations in Lyon. Transgene is listed on the regulated stock market in Paris (Euronext compartment B), with Institut Merieux as a major shareholder.